Enliven Therapeutics (ELVN) Net Cash Flow (2019 - 2026)

Enliven Therapeutics has disclosed Net Cash Flow across 8 years of filings, most recently posting $33.3 million for Q1 2026.

• Net Cash Flow for Q1 2026 came in at $33.3 million, up 248.17% year-over-year; the trailing twelve-month figure through Mar 2026 was $30.5 million (up 164.15% YoY), and the FY2025 annual result was -$25.3 million, down 205.42% from the prior year.
• Net Cash Flow came in at $33.3 million for Q1 2026 at Enliven Therapeutics, up from -$2.8 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $216.6 million in Q1 2023 to a low of -$166.4 million in Q2 2023.
• The 5-year median for Net Cash Flow is -$6.3 million (2022), against an average of $1.3 million.
• Peak annual rise in Net Cash Flow reached 2234.5% in 2023, while the deepest fall reached 2141.81% in 2023.
• Enliven Therapeutics' Net Cash Flow stood at -$10.6 million in 2022, then surged by 347.52% to $26.3 million in 2023, then slipped by 10.64% to $23.5 million in 2024, then slumped by 112.07% to -$2.8 million in 2025, then soared by 1273.77% to $33.3 million in 2026.
• The last three Net Cash Flow figures came in at $33.3 million (Q1 2026), -$2.8 million (Q4 2025), and -$17.7 million (Q3 2025), per Business Quant data.